Data Foundry

Drug recalls 2021

Naproxen Sodium Tablets — Class II drug recall D-0821-2021

Terminated recall by Glenmark Pharmaceuticals Inc., USA, reported 2021-09-29, distributed nationwide. CGMP Deviations

Recall numberD-0821-2021
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmGlenmark Pharmaceuticals Inc., USA, Mahwah, NJ, United States
Recall initiated2021-08-27
Classified2021-09-21
Reported by FDA2021-09-29
Terminated2023-10-04
DistributedNationwide (US)
Quantity9,552 bottles
Reason classescgmp
NDC68462-0178, 68462-0178-01, 68462-0178-05, 68462-0179, 68462-0179-01, 68462-0179-05, 68462-0188, 68462-0188-01, 68462-0188-05, 68462-0189, 68462-0189-01, 68462-0189-05, 68462-0190, 68462-0190-01, 68462-0190-05, 68462-0190-30, 68462-0190-50
Lot numbers29190087, 29190088, 29190089, 29200077, 29200078
Expiration dates2021-10-31, 2022-11-30

Product

Naproxen Sodium Tablets, USP 275 mg 100 Tablets Rx Only NDC 68462-178-01 Manufactured by: Glenmark Pharmaceuticals Inc., USA 4147 Goldmine Road Monroe, NC 28110 Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430

Reason for recall

CGMP Deviations

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0821-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.